Thomas WESSEL;Judy CARON;Timothy J. BARBERICH;Karim LALJI
发明人:
Karim LALJI,Timothy J. BARBERICH,Judy CARON,Thomas WESSEL
申请号：
US13305007
公开号：
US20120122874A1
申请日:
2011.11.28
申请国别(地区):
US
年份:
2012
代理人:
摘要：
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound； and a SRI, NRI, 5-HT2A modulator or DRI.
